Key FDA Decisions and Trial Results Expected in October
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 198
Did Agios Just Speed Up Its Business Plan by 2 Years?
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Is the FDA Changing Its Tune on Evoke Pharma?
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
Why Retrophin Shares Have Soared
Shares of Retrophin climbed early on Wednesday following positive top-line news from its mid-stage trial for the treatment of focal segmental glomerulosclerosis.
Why This Major Disappointment May Not Mark the End for Tonix Pharmaceuticals
Tonix Pharmaceuticals was the disaster of the day on Tuesday after the company announced that it will stop development of its fibromyalgia treatment after it failed in a late-stage trial.
Does Danaher’s Cepheid Deal Have More Sizzle Than Meets the Eye?
It is not uncommon for an acquirer to see its shares drop on news when it makes an acquisition. Still, when investors see both companies rise on a merger announcement then they automatically assume…
5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are…
Can Marijuana Help Alzheimer’s Patients?
This year marks a watershed in state legalization of marijuana, triggered by a change in social norms, the taxation yield promise, and the fact that, in many states, marijuana is already approved for medical…
How This Analyst Views Hillary Clinton’s Proposed Drug Price Hike Monitoring
One election year hot-button issue that is back on the table is the ongoing fight over drug prices. But the public has been debating drug prices for years now — long before the EpiPen…
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Why Boston Scientific Shares Could Rise Almost 40% More as Turnaround Continues
If the independent research firm Argus is correct, then Boston Scientific shareholders could see an upside of roughly 40% from the current price level.
Is Sunovion Overpaying for Cynapsus?
Shares of Cynapsus Therapeutics more than doubled on Thursday after it was announced that Sunovion Pharmaceuticals would be acquiring the company.
Suffering From Another Debacle, Theranos CEO Elizabeth Holmes Is One of the Least Powerful People In The World
According to The Wall Street Journal, blood testing company Theranos and its CEO Elizabeth Holmes have suffered a new, major setback.
3 Biotech Stocks Could Be the Next Big Takeover Targets
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Array BioPharma Continues Its Silent Rally With Mid-Stage Trial Win
Shares of Array BioPharma saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.